Jim Simons Novartis Ag Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q2 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Novartis Ag stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,298,151 shares of NVS stock, worth $301 Million. This represents 0.39% of its overall portfolio holdings.

Number of Shares

2,298,151

Previous 2,287,251 0.48%

Holding current value

$301 Million

Previous $255 Million 9.07%

% of portfolio

0.39%

Previous 0.41%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$101.96 - $121.01 $1.11 Million - $1.32 Million	10,900 Added 0.48%	2,298,151 $278 Million
Q1 2025 May 14, 2025	SELL	$97.14 - $115.57 $37.1 Million - $44.1 Million	-381,598 Reduced 14.3%	2,287,251 $255 Million
Q4 2024 Feb 13, 2025	BUY	$96.78 - $117.18 $35.6 Million - $43.1 Million	368,171 Added 16.0%	2,668,849 $260 Million
Q3 2024 Nov 13, 2024	SELL	$106.13 - $120.89 $21.1 Million - $24.1 Million	-199,104 Reduced 7.96%	2,300,678 $265 Million
Q2 2024 Aug 09, 2024	SELL	$92.57 - $107.37 $40.8 Million - $47.3 Million	-440,800 Reduced 14.99%	2,499,782 $266 Million
Q1 2024 May 13, 2024	BUY	$95.27 - $108.47 $9.77 Million - $11.1 Million	102,500 Added 3.61%	2,940,582 $284 Million
Q4 2023 Feb 13, 2024	BUY	$92.27 - $101.54 $18.6 Million - $20.4 Million	201,237 Added 7.63%	2,838,082 $287 Million
Q3 2023 Nov 14, 2023	BUY	$94.73 - $105.13 $26.7 Million - $29.6 Million	282,000 Added 11.98%	2,636,845 $269 Million
Q2 2023 Aug 11, 2023	SELL	$92.52 - $104.91 $64.1 Million - $72.7 Million	-692,599 Reduced 22.73%	2,354,845 $238 Million
Q1 2023 May 12, 2023	SELL	$80.03 - $92.81 $29.9 Million - $34.7 Million	-373,526 Reduced 10.92%	3,047,444 $280 Million
Q4 2022 Feb 13, 2023	BUY	$75.55 - $92.52 $18.1 Million - $22.1 Million	239,100 Added 7.51%	3,420,970 $310 Million
Q3 2022 Nov 14, 2022	SELL	$74.61 - $87.26 $44.9 Million - $52.5 Million	-601,500 Reduced 15.9%	3,181,870 $242 Million
Q2 2022 Aug 12, 2022	BUY	$80.52 - $93.75 $32.4 Million - $37.7 Million	402,200 Added 11.9%	3,783,370 $320 Million
Q1 2022 May 13, 2022	SELL	$80.11 - $90.62 $27.8 Million - $31.4 Million	-346,400 Reduced 9.29%	3,381,170 $297 Million
Q4 2021 Feb 11, 2022	BUY	$79.7 - $88.13 $33.5 Million - $37 Million	420,333 Added 12.71%	3,727,570 $326 Million
Q3 2021 Nov 12, 2021	BUY	$81.78 - $95.14 $73.4 Million - $85.4 Million	897,298 Added 37.23%	3,307,237 $270 Million
Q2 2021 Aug 13, 2021	BUY	$85.24 - $94.15 $3.38 Million - $3.73 Million	39,600 Added 1.67%	2,409,939 $220 Million
Q1 2021 May 13, 2021	SELL	$83.5 - $98.47 $199 Million - $235 Million	-2,387,994 Reduced 50.19%	2,370,339 $203 Million
Q4 2020 Feb 10, 2021	SELL	$78.07 - $94.43 $150 Million - $182 Million	-1,923,475 Reduced 28.79%	4,758,333 $449 Million
Q3 2020 Nov 13, 2020	SELL	$82.14 - $91.0 $132 Million - $147 Million	-1,612,800 Reduced 19.44%	6,681,808 $581 Million
Q2 2020 Aug 13, 2020	SELL	$80.93 - $91.1 $15.9 Million - $17.9 Million	-196,800 Reduced 2.32%	8,294,608 $724 Million
Q1 2020 May 14, 2020	BUY	$70.67 - $99.01 $134 Million - $187 Million	1,890,226 Added 28.63%	8,491,408 $700 Million
Q4 2019 Feb 13, 2020	BUY	$84.35 - $95.37 $118 Million - $133 Million	1,396,027 Added 26.82%	6,601,182 $625 Million
Q3 2019 Nov 13, 2019	BUY	$85.54 - $94.26 $97.2 Million - $107 Million	1,135,798 Added 27.91%	5,205,155 $452 Million
Q2 2019 Aug 12, 2019	BUY	$75.4 - $92.8 $64.5 Million - $79.3 Million	854,857 Added 26.59%	4,069,357 $372 Million
Q1 2019 May 14, 2019	SELL	$75.32 - $86.15 $21.2 Million - $24.3 Million	-281,998 Reduced 8.07%	3,214,500 $309 Million
Q4 2018 Feb 13, 2019	BUY	$73.66 - $82.02 $258 Million - $287 Million	3,496,498 New	3,496,498 $300 Million

Others Institutions Holding NVS

# of Institutions

1,561

Shares Held

136M

Call Options Held

1.72M

Put Options Held

1.7M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $281B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account